Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

BetterLife Pharma (NPAU) AI Stock Analysis

DE:NPAU

BetterLife Pharma

(Frankfurt:NPAU)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improving cash disciplineImproved cash-burn performance suggests tighter spending control and better operational discipline than in earlier periods. Although the company remains cash-flow negative, continued stabilization could extend its runway and make future financing needs more manageable over the next several quarters.
Negative Factors
No reported revenueThe absence of reported revenue means the business has not yet demonstrated commercial demand or an internally generated operating base. Until a product or other revenue source emerges, financial performance remains dependent on development progress and access to external funding.

BetterLife Pharma (NPAU) vs. iShares MSCI Germany ETF (EWG)

-200%0%200%400%600%800%DE:NPAU+341.18%EWG+6.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 110.87M
Dividend Yield
―
Average Volume (3M)
20.10K
Price to Earnings (P/E)
-10.9
Beta (1Y)
1.19
Revenue Growth
―
EPS Growth
-248.72%
Country
Germany
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

BetterLife Pharma Business Overview & Revenue Model

Company Description

BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-ba...

BetterLife Pharma Risk Analysis

BetterLife Pharma disclosed 20 risk factors in its most recent earnings report. BetterLife Pharma reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

BetterLife Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:NPAU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:MDMATSE:MDMA50NeutralCAD 18.57M-12.42-72.15%―224.46%28.37%
TSE:PHRMTSE:PHRM48NeutralCAD 5.01M-14.29-75.59%――75.84%
TSE:MRVLTSE:MRVL46NeutralCAD 7.56M-4.4939.05%――25.70%
TSE:CSCITSE:CSCI42NeutralCAD 8.37M-0.47-48.52%―-13.00%75.31%
TSE:MOODTSE:MOOD42NeutralCAD 680.99K-0.57-85.01%―73.76%-108.30%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%DE:NPAUTSE:CSCITSE:PHRMTSE:MRVLTSE:MOODTSE:MDMADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:NPAU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:NPAUBetterlife Pharma Inc.0.150.12383.87%
TSE:CSCICosciens Biopharma Inc.8.50-2.06-19.50%
TSE:PHRMPharmaTher Holdings Ltd0.06-0.05-45.45%
TSE:MRVLMarvel Biosciences Corp0.12-0.10-44.19%
TSE:MOODDoseology Sciences, Inc.0.09-0.26-75.71%
TSE:MDMAPharmAla Biotech Holdings, Inc.0.180.0760.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.